## INCY: Incyte Corporation - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 0.5% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($90.35)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 3
- **Sentiment:** Bullish (Bullish: 3, Bearish: 0)

**1. Incyte Corp. stock outperforms competitors on strong trading day**
- Source: MarketWatch | 20251215T163000 | Bullish | Relevance: 100%
- Incyte Corp. (INCY) shares rose 3.39% to $98.64 on a challenging trading day, outperforming the S&P 500 and Dow Jones Industrial Average which experienced slight declines. Despite the gain, Incyte Corp. closed 9.73% below its 52-week high of $109.28 reached on November 12th. The article highlights Incyte's strong performance relative to the broader market.

**2. Is Incyte Stock Outperforming the Nasdaq?**
- Source: Palmetto Grain Brokerage | 20251215T072100 | Bullish | Relevance: 100%
- Incyte Corporation (INCY) has demonstrated strong stock performance, outperforming the Nasdaq Composite (NASX) across various timeframes, including the past three months, year-to-date, and the past 52 weeks. The company reported better-than-expected Q3 2025 results with increased revenue and raised full-year guidance, although the stock saw a slight dip on the announcement day. Analysts maintain a "Moderate Buy" rating for INCY, with a mean price target suggesting an upside to current levels.

**3. Incyteâ€™s latest study completion: A step forward in drug interaction insights**
- Source: MSN | 20251216T010832 | Bullish | Relevance: 100%
- The article reports that Incyte has completed its latest study. This completion marks a step forward in gaining drug interaction insights, though no specific drug or study details are provided in this brief update.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 4, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-08 | Morgan Stanley | $92 | $86 | +7% |
| 2025-12-08 | Wells Fargo | $116 | $97 | +20% |
| 2025-12-08 | Mizuho | $121 | $90 | +34% |
| 2025-11-24 | Barclays | $115 | $101 | +14% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-08 | Morgan Stanley | main | Equal-Weight |
| 2025-12-08 | Wells Fargo | main | Overweight |
| 2025-12-08 | Mizuho | up | Outperform |
| 2025-11-24 | Barclays | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 6 ($0.08M) |
| Sells | 17 ($23.81M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 59.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Baker Bros. Advisors: 15.7% (0.0%)
- Vanguard Group Inc: 10.2% (-0.9%)
- Blackrock Inc.: 9.1% (-0.3%)
- Dodge & Cox Inc.: 7.1% (-4.5%)
- State Street Corpora: 4.9% (-2.0%)

### Key Risks

1. Heavy insider selling: $24M sold (17 transactions in 90 days).
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 4 raises (avg +19%) could attract flows.
- Momentum building: MRS_10 improving +6.6% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 0.12 indicates undervaluation relative to growth. Forward P/E 12.6x attractive for 13% earnings growth. Quality metrics strong (ROE 30%, ROA 14%, margin 25%). Balance sheet: strong liquidity (3.2x), low leverage (D/E 0.36). Analyst sentiment positive (4 raises, avg +19%). Insider selling cluster ($23.8M in 90 days), potential headwind. Institutional flow bullish (4 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $19.0B |
| Beta | 0.81 |
| 52W Range | $53.56 - $109.28 |
| Short Interest | 6.6% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.12 |
| Forward P/E | 12.6 |
| Current P/E | 14.2 |
| YoY Growth | 12.7% |
| EPS Direction | RISING |

### Technicals

MRS_10 strengthening from -6.1% to 0.5% (+6.6% in 5 days), confirming momentum buildup. Below STRENGTH zone by 2.5pp (needs >3.0% for momentum thesis). MRS_5 at 1.5% confirms short-term momentum alignment. Long-term uptrend intact (above SMA200 at 1.25x) but short-term weakness (below SMA20). MACD histogram bearish (-0.94), momentum weakening. RSI neutral at 45. OFD pattern: -STN (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 0.49% (CS: 40) | Neutral |
| RSI_14 | 44.9 | Neutral |
| MACD Histogram | -0.94 | Bearish |
| vs SMA20 | 0.964x | Below |
| vs SMA50 | 1.001x | Above |
| vs SMA200 | 1.254x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $97.03
- **Stop Loss:** $90.35 (6.9% risk)
- **Target:** $103.71 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 149
- **Position Value:** $14,457.47
- **Portfolio %:** 14.46%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with balanced risk positioning. VIX remains calm at 16.48 while breadth shows modest improvement to 52%, indicating neither euphoria nor distress. Mixed sectoral themes from energy weakness to AI expansion suggest stock-picking environment rather than broad directional moves.*

### Earnings

**Next:** 2026-02-09 (Est: $1.89)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.64 | $2.26 | +38.0% |
| 2025Q2 | $1.47 | $1.57 | +6.6% |
| 2025Q1 | $1.03 | $1.16 | +12.3% |
| 2024Q4 | $1.55 | $1.43 | -8.0% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*